Home Applications 022030 Application 022030
Type NDA
Sponsor PFIZER Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 TOVIAZ FESOTERODINE FUMARATE TABLET, EXTENDED RELEASE;ORAL 4MG Yes No 002 TOVIAZ FESOTERODINE FUMARATE TABLET, EXTENDED RELEASE;ORAL 8MG Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N022030-001 TOVIAZ FESOTERODINE FUMARATE 4MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2008-10-31 N022030-002 TOVIAZ FESOTERODINE FUMARATE 8MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2008-10-31
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 2 matching rows.
Orange Book patents# Current patent rows page 1 of 1 · 12 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N022030-001 7807715 2027-06-07 U-913 Drug product N022030-001 8088398 2027-06-07 U-913 Drug product N022030-001 8501723 2027-06-07 Drug product 2013-08-20 N022030-001 7807715*PED 2027-12-07 Pediatric extension N022030-001 8088398*PED 2027-12-07 Pediatric extension N022030-001 8501723*PED 2027-12-07 Pediatric extension N022030-002 7807715 2027-06-07 U-913 Drug product N022030-002 8088398 2027-06-07 U-913 Drug product N022030-002 8501723 2027-06-07 Drug product 2013-08-20 N022030-002 7807715*PED 2027-12-07 Pediatric extension N022030-002 8088398*PED 2027-12-07 Pediatric extension N022030-002 8501723*PED 2027-12-07 Pediatric extension
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 3 of 3 · 90 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N022030-001 TOVIAZ 4MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2008-10-31 3a93d1ddd44b…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N022030-002 TOVIAZ 8MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2008-10-31 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N022030-001 TOVIAZ 4MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2008-10-31 f41ea6bd6efb…2022-10-28 04:53 UTC 2022-10 N022030-002 TOVIAZ 8MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2008-10-31 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N022030-001 TOVIAZ 4MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2008-10-31 e64feba35796…2022-09-29 23:25 UTC 2022-09 N022030-002 TOVIAZ 8MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2008-10-31 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N022030-001 TOVIAZ 4MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2008-10-31 cb3db0bc1861…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N022030-002 TOVIAZ 8MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2008-10-31 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N022030-001 TOVIAZ 4MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2008-10-31 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N022030-002 TOVIAZ 8MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2008-10-31 a50c72e98297…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 3 · 90 observed states.
Observed Orange Book patent history# Patent history page 1 of 15 · 592 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N022030-001 7807715 2027-06-07 U-913 Drug product d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-001 8088398 2027-06-07 U-913 Drug product d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-001 8501723 2027-06-07 Drug product 2013-08-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-001 7807715*PED 2027-12-07 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-001 8088398*PED 2027-12-07 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-001 8501723*PED 2027-12-07 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-002 7807715 2027-06-07 U-913 Drug product d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-002 8088398 2027-06-07 U-913 Drug product d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-002 8501723 2027-06-07 Drug product 2013-08-20 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-002 7807715*PED 2027-12-07 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-002 8088398*PED 2027-12-07 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N022030-002 8501723*PED 2027-12-07 Pediatric extension d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N022030-001 7807715 2027-06-07 U-913 Drug product c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-001 8088398 2027-06-07 U-913 Drug product c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-001 8501723 2027-06-07 Drug product 2013-08-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-001 7807715*PED 2027-12-07 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-001 8088398*PED 2027-12-07 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-001 8501723*PED 2027-12-07 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-002 7807715 2027-06-07 U-913 Drug product c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-002 8088398 2027-06-07 U-913 Drug product c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-002 8501723 2027-06-07 Drug product 2013-08-20 c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-002 7807715*PED 2027-12-07 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-002 8088398*PED 2027-12-07 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N022030-002 8501723*PED 2027-12-07 Pediatric extension c2088c7a36db…2026-09-14 22:38:34 2026-08 N022030-001 7807715 2027-06-07 U-913 Drug product 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-001 8088398 2027-06-07 U-913 Drug product 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-001 8501723 2027-06-07 Drug product 2013-08-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-001 7807715*PED 2027-12-07 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-001 8088398*PED 2027-12-07 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-001 8501723*PED 2027-12-07 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-002 7807715 2027-06-07 U-913 Drug product 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-002 8088398 2027-06-07 U-913 Drug product 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-002 8501723 2027-06-07 Drug product 2013-08-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-002 7807715*PED 2027-12-07 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-002 8088398*PED 2027-12-07 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022030-002 8501723*PED 2027-12-07 Pediatric extension 84e616aacf4f…2026-08-18 06:07:40 2026-07 N022030-001 7807715 2027-06-07 U-913 Drug product caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022030-001 8088398 2027-06-07 U-913 Drug product caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022030-001 8501723 2027-06-07 Drug product 2013-08-20 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022030-001 7807715*PED 2027-12-07 Pediatric extension caaa826d4ba7…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 3 · 108 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 40 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0069-0242 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0242 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0242 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0242 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0242 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0242 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0242 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0242 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0244 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0244 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0244 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0244 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0244 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0244 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0244 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 0069-0244 Toviaz fesoterodine fumarate Pfizer Laboratories Div Pfizer Inc NDA Current 55154-2737 Toviaz fesoterodine fumarate Cardinal Health NDA Current 55154-2737 Toviaz fesoterodine fumarate Cardinal Health NDA Current 55154-2737 Toviaz fesoterodine fumarate Cardinal Health NDA Current 55154-2738 Toviaz fesoterodine fumarate Cardinal Health NDA Current 55154-2738 Toviaz fesoterodine fumarate Cardinal Health NDA Current 55154-2738 Toviaz fesoterodine fumarate Cardinal Health NDA Current 63539-183 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-183 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-183 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-183 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-183 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-183 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-183 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-183 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-242 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-242 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-242 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-242 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-242 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-242 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-242 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 63539-242 Toviaz fesoterodine fumarate U.S. Pharmaceuticals NDA Current 69189-0242 Toviaz fesoterodine fumarate Avera McKennan Hospital NDA Current 69189-0244 Toviaz fesoterodine fumarate Avera McKennan Hospital NDA Current